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In 1984 we started a prospective controlled trial comparing en-
doscopic sclerotherapy (ES) with the distal splenorenal shunt
(DSRS) in the elective treatment of variceal hemorrhage in cir-
rhotic patients. The study population included 40 patients with
cirrhosis and portal hypertension referred to our department from
October 1984 to March 1988. These patients were drawn from
a pool of 173 patients who underwent either elective surgery or
endoscopic sclerotherapy during this time. Patients were assigned
to one of the two groups according to a random-number table:
20 to DSRS and 20 to ES. During the postoperative period, no
DSRS patient died, while one ES patient died of uncontrolled
hemorrhage. One DSRS patient had mild recurrent variceal
hemorrhage despite an angiographically patent DSRS. Four ES
patients suffered at least one episode of gastrointestinal bleeding:
two from varices and two from esophageal ulcerations. Five ES
patients developed transitory dysphagia. Long-term follow-up
was complete in all patients. Two-year survival rates for shunt
(95%) and ES (90%) groups were similar. One DSRS patient
rebled from duodenal ulcer, while three ES patients had recurrent
bleeding from esophagogastric sources (two from varices and
one from hypertensive gastropathy). One DSRS and two ES
patients have evolved a mild chronic encephalopathy, four DSRS
and two ES patients suffered at least one episode of acute en-
cephalopathy. Two ES patients had esophageal stenoses, which
were successfully dilated. Preliminary data from this trial seem
to indicate that DSRS, in a subgroup of patients with good liver
function and a correct portal-azygos disconnection, more effec-
tively prevents variceal rebleeding than ES. However no signif-
icant difference in the survival of the two treatment groups was
noted.
Tn HE SELECTIVE DISTAL splenorenal shunt (DSRS)
proposed by Warren et al.' in 1967 appeared to
be the best procedure available for surgical de-
compression of patients with portal hypertension.2" It
seemed to combine the advantages ofthe definitive treat-
From the the Department of Surgical Semeiology,* Sixth
Surgical Clinic,t San Paolo Institute of Biomedical Science,
First Surgical Clinic,4 University of Milan, and
First Department of Medicine,¶ the San Paolo
Institute of Biomedical Science, and from the
Second Department of Surgery, || Milan, Italy
ment of varices, typical oftotally diverting shunts, without
harmful loss of hepatopetal portal flow. This resulted in
a better quality of life, as reported in several studies com-
paring the clinical results of selective and nonselective
shunts.39
It has been shown that endoscopic sclerotherapy (ES)
protects against variceal rebleeding when compared to a
medical regimen1012 and improves long-term survival,'3
resulting in a possible alternative to shunt surgery.
To evaluate the efficacy of these treatments, we started
a prospective controlled trial in 1984 comparing the ef-
ficacy of ES and DSRS in the prevention of variceal re-
bleeding in cirrhotic patients.'7
Our study is similar to three recently published ran-
domized controlled trials.'1'6
Methods
The study population comprised 40 patients with cir-
rhosis and portal hypertension referred to our department
from October 1984 to March 1988. These patients were
drawn from a pool of 173 patients who underwent either
elective surgery or endoscopic sclerotherapy because of
portal hypertension during this time.
The criteria for inclusion into the study were (1) liver
cirrhosis confirmed by biopsy in all patients; (2) endo-
scopic documentation of variceal hemorrhage (actively
bleeding varix or nonbleeding varices without other le-
sions) requiring at least one unit ofblood transfusion; (3)
arrest of acute variceal hemorrhage either spontaneously
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or by use ofintravenous vasopressin and/or somatostatin
and/or balloon tamponade and/or hemostatic sessions of
ES; (4) patient age of less than 70 years; (5) good or mod-
erate liver function (Child's A and B class);18 (6) patency
of the splanchnic venous system and hepatopetal portal
flow (according to Nordlinger's classification);'9 (7) eligible
for either shunt or ES; (8) absence of life-threatening dis-
eases (i.e., tumors); and (9) willingness to return for regular
sclerosis and follow-up. Patients bleeding from gastric
varices were excluded. Figure 1 shows the reasons for the
exclusion of 133 patients. Randomization was done when
the patient was stabilized, no more than 24 hours before
treatment. Patients were assigned to one ofthe two groups
according to a random-number table. Informed written
consent was obtained from all patients before their inclu-
sion in the study. No patient refused the assigned treat-
ment. Variceal rebleeding within 2 years offirst treatment
was considered the primary measure of patient outcome.
The sample requirements to show a decrease in variceal
rebleeding from 43% to 7% are about 20 patients for each
group, applying standard power (90%), type I error (p
< 0.05) and a two-tailed t test.20
Preoperative Evaluation
A complete medical history was obtained in each pa-
tient with particular attention to previous episodes ofgas-
trointestinal bleeding and evidence of either primary or
posthemorrhagic hepatic failure (jaundice, ascites, or
edema). Physical examination concentrated on the as-
sessment of the nutritional state and the presence of he-
patosplenomegaly, jaundice, ascites, and edema. Routine
laboratory tests were performed to evaluate liver function
(Table 1). An overall assessment of the severity of liver
disease (hepatic score index) was made at the time of pa-
tient inclusion in the study to complete Child's classifi-
cation and adequately compare the two groups of pa-
tients.3 A score from 1 to 3 according to the level ofseverity
was assigned to each clinical and laboratory parameter.
The total of the scores, the maximum ofwhich is 27, was
called the hepatic score sum. It is often impossible to
compare different hepatic score sums because of missed
parameters in some patients. Thus the hepatic score index
was expressed as the ratio of the hepatic score sum to the
highest possible hepatic score sum. Serum alfafeto-protein
and ultrasonography were routinely obtained to screen
the presence ofhepatic neoplasm. The etiology ofcirrhosis
was determined from clinical history, serum markers of
viral hepatitis and liver biopsy. The presence ofesophageal
varices was assessed through endoscopic examination.
Criteria used for classifying the endoscopic findings were
based on the General Rules for Recording Endoscopic
Findings on Esophageal Varices compiled by the Japanese
Research Society for Portal Hypertension.2'
Cerebral function was assessed through a complete
neurologic examination, taking into account the mental
state, asterixis, electroencephalographic findings (EEG),
and the trail making test.21'23 All parameters were assessed
219 patients admitted
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TABLE 1. Characteristics ofPatients
DSRS ES
Characteristic (n = 20) (n = 20)
Age (years) 46.9 ± 10.3 51.2 ± 8.2
Sex M/F 11/9 16/4
Etiology*
Alcoholic 2 13
Nonalcoholic 18 7
Child's class
A 8 7
B 12 13
Hepatic score 0.52 ± 0.05 0.58 ± 0.08
Prothrombin time (%)
>80 2 5
80-50 15 1 1
<50 3 4
Bilirubin (mg/dL)
<1.2 13 9
1.2-3 7 8
>3 0 3
Albumin (gr/dL)
>3 18 18
3-2.5 2 2
<2.5 0 0
Portal perfusion
Degree I 36% 27%
II 53% 40%
III 12% 33%
N. of previous bleeding 2.3 ± 1.7 1.9 ± 1.0
N. of blood unit 3.1 ± 2.3 2.2 ± 2.1
Interval between bleeding and
treatment (months) 3.2 ± 2.3 3.1 ± 2.4
N. of previous
encephalopathy episodes 5 5
Easily controlled preoperative
ascites 2 3
* Alcoholic versus nonalcoholic: p = 0.0031.
using the 0 to 4 rating system proposed by Conn.24 The
"Cancelling A's" test was also used25 and rated with the
same method. Each parameter was arbitrarily weighted
in proportion to its importance. Mental state was assigned
a factor of 4, asterixis and EEG a factor of 1, and each of
the others a factor of 0.5. An overall score for hepatic
encephalopathy (HE) was calculated from the sum ofthe
values for each of the five parameters.4 We called HE
"acute" if it was precipitated by gastrointestinal bleeding,
heavy drinking, pharmacologic or dietary imbalances, of
brief duration and easily controlled with elimination of
precipitating cause. We called HE chronic if it was spon-
taneous, of long duration, and more difficult to manage.
Naturally preoperative HE was excluded in all patients.
A visceral angiogram was obtained by selective cathe-
terization of celiac axis and superior mesenteric artery.
The degree of hepatic perfusion was evaluated according
to Nordlinger's criteria.'9 The rate of contrast (sodium
and meglumine ioxaglate, Hexabrix 320-Byk Gulden,
Milan, Italy) infusion was 6 mL/seconds X 10 seconds.
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Operative Management
All shunts were performed by a single experienced sur-
gical team.26 DSRS was constructed according to the
technique described by Warren27 ( 15 cases). In five cases
a splenopancreatic disconnection28 was performed as a
technical addition to DSRS, offering the optimum surgical
therapy to each patient.
Endoscopic variceal sclerosis was conducted by two
endoscopists with extensive experience in this field.29 All
patients were given 5 to 10 mg diazepam premedication.
ES was performed using an Olympus GIF IT (Lorenzatto,
Torino, Italy) flexible endoscope or an electronic Welch
Allyn videoendoscope (Coresea, Milan, Italy). At each
session 10 to 50 mL ofpolidocanol (0.5% to 1%) (Athoxy-
sclerol, Creusller) and 0.5% methylene blue were injected
using a flexible injection needle in the area 5 to 7 cm
above the esophagogastric junction. Methylene blue al-
lowed visual confirmation of intravariceal and paravari-
ceal injections.
Postoperative Evaluation
In the evaluation ofthe hospital mortality rate and early
complications, we defined the first 30 days after the initial
treatment as the postoperative period. In the ES group,
the events that occurred during the interval between the
first session and eradication were also recorded and eval-
uated.
In the postoperative period, esophageal endoscopy was
performed in each patient. A visceral angiography was
performed on the 10th average postoperative day only in
patients having DSRS. Shunt patency was verified in ve-
nous phase of angiograms in the DSRS group. In the ES
group, the number of further sessions depended on the
findings obtained at endoscopy performed 1 week after
the first sclerosis session. As soon as the eradication was
achieved, the patient was included in the follow-up pro-
gram. The remaining ES patients underwent further scle-
rosis sessions if they were free of complications such
as mucosal ulcerations, symptomatic stricture, severe
esophagitis, fever, and pneumonia. In the presence of
complications, an upper endoscopy was performed at in-
tervals of seven to ten days and further ES sessions were
considered only when complications were resolved. Dur-
ing the follow-up period, DSRS patients were checked the
first, third, and sixth month after discharge and then at
least twice yearly, on an outpatient basis. Follow-up en-
doscopy was scheduled 4 to 6 weeks after the last session
and then at 6-month intervals, unless recurrent hemor-
rhage occurred.
At each visit, liver function was evaluated after a com-
plete medical examination and laboratory tests. Longi-
tudinal assessment of liver function was quantified using
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an arbitrary score calculated on the basis of several stan-
dard laboratory tests. Synthesis activity (albumin and
prothrombin time determinations), excretion (bilirubin
and alkaline phosphatase levels) and the presence of he-
patocellular necrosis (serum glutamic-oxaloacetic trans-
aminase determinations) were quantified by the same
method previously described for the preoperative assess-
ment ofglobal functional hepatic reserve.3 This index was
obtained yearly after treatment and compared each time
with preoperative values. It was only used for the longi-
tudinal assessment of liver function and termed longitu-
dinal hepatic score index. Child's classification and the
preoperative hepatic score index were not suitable to fol-
low-up because some parameters could not be assessed
over a long period of time.
The assessment ofthe neurologic status was performed
using the above-mentioned criteria. An EEG was obtained
at least once a year. A return to drinking was based on
patient's statements, our own assessment, and information
from relatives. Continued drinking was defined as daily
consumption in excess of 1 L of wine and/or spirits. All
patients were on a 10-meq sodium and protein-balanced
diet (1 g protein/Kg body weight) and undergoing lactulose
prophylactic treatment: the initial dose was 60 g/day in
three separate doses and adjusted thereafter to induce at
least one bowel movement per day.
Definitions
Eradication was defined as absence of varices or pres-
ence of Fl white varices. Rebleeding was defined as hem-
orrhage due to esophagogastric varices and/or congestive
gastropathy that required at least one unit blood trans-
fusion and was designated as being from varices if sup-
ported by endoscopic findings. The ideal treatment of
variceal rebleeding was emergency sclerotherapy. Chronic
rebleeding from congestive gastropathy was treated with
beta-blocking therapy.30 Rebleeding due to peptic ulcer
was recorded separately.
The risk of hospitalization for HE was defined by taking
the number of late hospital admissions due to episodes
of HE and dividing it by the total number of patients
evaluated in the follow-up period.
Death, whatever the cause, was considered failure of
therapy in both groups. Failure of shunt was defined as
shunt thrombosis on follow-up angiographic evaluation.
Sclerotherapy failure was defined as a change to surgery
due to recurrent hemorrhage or severe complications that
prevented further ES. This decision was taken by the en-
doscopists and surgeon and was not based on a specific
number or degree of severity of the recurrent bleeding
episodes.
Data Management and Statistical Analysis
Initial evaluation and subsequent follow-up data were
collected on databases (Excel, Microsoft Corp., Cologno,
Monzese, Italy) for computer input (Epson PC AX com-
puter, Seiko Epson Corporation) and subsequent analysis
(Microstat, Ecosoft Inc., Indianapolis, IN). Survival and
therapy failures were analyzed by the Kaplan-Meier
method and were compared by the log-rank test.31 Com-
parison between groups was made by chi square test for
proportions and Student's t test for the means.
Results
In the ES group, varices were completely eradicated in
19 patients (95%): one patient died before eradication.
The number of injection sessions were 3.1 ± 1.1 (95% CI
from 2.6 to 3.6 months), occurring over 4.8 ± 3.7 months
(95% CI from 3.2 to 6.4 months) and the mean amount
of polydocanol required for eradication was 89.4 ± 43.6
mL (95% CI from 70 to 108.7 mL).
During the postoperative period, no DSRS patient died,
while one ES patient died of uncontrolled hemorrhage
after the first sclerosis session. One DSRS patient had mild
recurrent variceal hemorrhage controlled by conservative
therapy, despite an angiographically patent shunt. Four
ES patients suffered at least one episode ofgastrointestinal
bleeding. Two were from varices requiring emergency
variceal sclerotherapy and two from esophageal ulcera-
tions, which were managed conservatively. No patient had
episodes of hepatic encephalopathy. Five ES patients de-
veloped transitory dysphagia due to esophageal ulcera-
tions. One ES patient suffered pleural space effusion.
The mean follow-up in the DSRS group was 29.2 ± 11.4
months (95% CI from 24.2 to 34.1 months) and the mean
follow-up in the ES group was 23.8 ± 14.8 months (95%
CI from 23.8 to 30.3 months). Two-year survival rates for
shunt (95%) and ES (90%) groups were similar (Fig. 2).
One DSRS patient died of intestinal obstruction, one of
liver cancer and one of heart failure. One ES patient died
of hepatic failure and one of unknown causes. Failure of
therapy was at that moment equal to the death rate: no
patient had shunt thrombosis or changed treatment. In
the ES group, varices reformed in 5 of 19 eradicated pa-
tients (26%) after 8.6 ± 7.4 months (95% CI from 2 to
15.3 months). They were successfully re-eradicated. No
DSRS patient had variceal rebleeding (one DSRS patient
rebled from duodenal ulcer), while two ES patients had
recurrent hemorrhage from varices and one from hyper-
tensive gastropathy. The global percentage ofpatients who
rebled was 5% and 35%, respectively (p = 0.04). Actuarial
curves of patients free from esophagogastric rebleeding,
for the two groups, confirmed the efficacy of DSRS (Fig.
3). One DSRS and two ES patients developed mild chronic
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FIG. 2. Actuarial survival curves for distal splenorenal shunt (DSRS) and endoscopic sclerotherapy (ES). The vertical axis indicates the survival rate.
No significant difference was noted using the log-rank test.
encephalopathy. Four DSRS and 2 ES patients suffered
at least 1 episode of acute encephalopathy (p was not sig-
nificant): 2 (1 DSRS and 1 ES) due to pharmacologic
imbalance, 2 (1 DSRS and 1 ES) due to heavy drinking,
100%
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months 1 2 24
1 DSRS due to dietary abuse and 1 DSRS due to severe
hyperglycemia. The results of trail-making test (TMT),
cancelling A's test and electroencephalography (EEG)
confirmed the similar outcome in the two groups of pa-
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FIG. 3. Actuarial curves of patients free from gastroesophageal rebleeding for distal splenorenal shunt (DSRS) and endoscopic sclerotherapy (ES).
The vertical axis indicates the rate of patients free of gastroesophageal rebleeding. The DSRS group has significantly prevented gastroesophageal
rebleeding compared to ES (p < 0.05) using the log-rank test.
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TABLE 2. Comparison ofthe Results of TMT,
Cancelling A's Test, and EEG
Long-Term
Period Preoperative Follow-up
TMT (sec.)
DSRS 50.8 ± 20.5 52.1 ± 21.3
ES 61.9 ± 17.9 60.2 ± 24.5
A's test*
DSRS 4.4 ± 3.1 3.5 ± 3.3
ES 5.8 ± 4.5 5.2 ± 3.5
EEG (% abnormal)t
DSRS 15% 20%
ES 15% 21%
* Refers to the number of A's the patients have omitted to cancel in
the test.
t p value not significant for all comparisons.
tients on yearly examination (Table 2). The risk of hos-
pitalization for HE was similar: 0.25 ± 0.9 and 0.21 ± 0.7
after DSRS and ES, respectively (p was not significant).
One DSRS patient (5%) and four ES patients (21 %) went
back to drinking (p was not significant). Two ES patients
had esophageal stenosis that were successfully dilated. As-
cites developed in two DSRS patients (5%) and in ten ES
patients (53%; p = 0.01). Longitudinal data of liver func-
tion tests were available on 18 ES and 19 DSRS patients
at 1 year. ES did not cause changes in hepatic function
(from 0.53 ± 0.14 to 0.53 ± 0.14), whereas after the DSRS
procedure there was significant impairment in function
at 1 year (from 0.54 ± 0.10 to 0.61 ± 0.11; p = 0.012).
Discussion
The pattern of a randomized controlled trial (RCT),
comparing surgical treatment with a conservative therapy
like ES, is often a complicated process requiring a choice
ofend-point patient selection criteria, treatment schedules,
and methods of patient evaluation. Three RCTs,14-16 in
addition to our study, have been published comparing
DSRS to ES. They show different approaches to these
issues.
It is true that survival is the primary end-point in pro-
spective studies. In two studies'4"16 the definition ofmajor
end-point was not specified (survival, prevention of re-
current bleeding, and maintenance of hepatic function)
and no statistical method for determining trial size was
used. The study of Teres et al.'5 was designed to observe
an increase in survival. However the expected increase
seems to be too optimistic. On the basis of the available
data,2 5">'3 the sample requirements to show a realistic
increase in survival at 5 years of the 10% is about 470
patients per group, applying standard power (80%), type
I error (p < 0.05) and a two-tailed t test.20
Because gastroesophageal rebleeding was the most life-
threatening complication in ES, we wanted to verify if
DSRS was more effective in the prevention of rebleeding
than ES and evaluate if this improvement affected sur-
vival. We limited the necessary recruitment to 20 patients
per group, so the trial needed only one surgical team. This
is a general problem in surgical multicenter trials, as the
surgeon's skill is a major factor in the outcome of the
patients, especially when a technically complex operation
like DSRS is used.32 Our trial was undertaken after the
team had acquired experience with 80 selective shunts,
to ensure a fairly good standardization of the surgical ap-
proach and intraoperative and postoperative treatment.5
However the patient's inclusion has not been stopped at
20 cases for each group. In fact the random choice in our
trial does not prevent a problem reported in Table 1, which
shows a statistical difference in etiology between the two
groups. Although our experience did not attribute a prog-
nostic role to etiology,3'33 some studies indicated a more
favorable prognosis for survival in nonalcoholics com-
pared to alcoholics.34'35 We then decided to increase the
number of patients to be recruited either to eliminate the
difference or carry out a subgroup analysis.
This study also differs from the other RCTs'4-'6 because
of the trial design, particularly if we consider the criteria
of inclusion and exclusion and the number of patients
seen and rejected. Figure 1 shows the criteria of exclusion
used in our trial. Some choice in the study design caused
an increase in the number of patients rejected. In fact 219
patients were admitted to our department: 22 patients
were considered to have had no previous variceal bleeding
and had prophylactic treatment, and 24 patients had active
variceal bleeding that was treated on an emergency basis.
They were excluded because they received definitive
treatment (portocaval shunt, esophageal transection) or
were lost or died after hemostatic session of sclerotherapy.
Ninety-one of 173 patients evaluated were not eligible for
inclusion in the study. Finally 13 patients were unwilling
to return for regular sclerosis and 24 patients were not
included because they had not undergone preoperative
angiography or were sent to us with previous indications
to DSRS or sclerosis. Our selection criteria excluded 77%
of patients with previous variceal bleeding. This value was
similar to that reported in another study (83%). '4 Other
studies' 5"6 excluded fewer patients (44% and 62%, re-
spectively). However Teres et al.'5 had additional exclu-
sions after randomization (16%) due to technical reasons.
The results of these trials' 17 confirm previous results
showing that DSRS is more effective in preventing variceal
rebleeding than ES (Table 3). Gastroesophageal rebleeding
after DSRS can be caused by either gastroduodenal lesions
or esophageal varices. The most common cause of variceal
rebleeding is shunt thrombosis, but hemorrhage can also
occur when the shunt is patent because of renal vein hy-
36pertension.
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TABLE 3. Two-Year Survival and Rebleeding Rate in Randomized Controlled Trials Comparing DSRS with ES
Warren'4 Teres'5 Rikkers'6 Our Data
Two-year survival rate after DSRS 59% 71% 65% 95%
Two-year survival rate after ES 84% 68% 61% 90%
Child's C patients 43% 0 33% 0
Interval between bleeding and treatment (days) >3-5 10-15 NR 90*
Rebleeding rate after DSRS 3%t 14%t 19%t 5%t
Rebleeding rate after ES 53%t 37%t 57%t 35%t
Variceal eradication rate NR 46% 63% 95%
Failure to salvage rebleeders 17% 33% 47% 14%
Shunt for ES failure 31% 6% 7% 0
Global mortality rate due to rebleeding 3% 14% 27% 5%
Global mortality rate due to other causes 13% 16% 13% 10%
NR, not reported.
* Mean value.
tp < 0.05.
The problem of rebleeding in the ES group is complex
and is related to factors such as the number of patients
with eradicated varices, the time interval required for
eradication, the incidence of sclerosis-induced mucosal
ulcerations of the esophageal wall, the variceal relapses
after eradication, and the incidence of hypertensive gas-
tropathy.37 Our incidence of rebleeding (35%) is similar
to that reported by Teres et al.,"5 but lower compared to
other studies.'4"6 The importance of the different tech-
niques to explain these differences is not clear.38'39 It is
obvious that a more aggressive technique of ES, charac-
terized by endoscopic examinations at shorter intervals
or by more ES sessions, could be more effective in pre-
venting variceal rebleeding. However this potential benefit
could be cancelled by a higher risk of rebleeding from
sclerosis-induced mucosal ulcerations. Our sclerotherapy
regimen did not follow a rigid time protocol. Because of
the unpredictability of individual responses, it is unlikely
that an optimal schedule can be suitable to all patients.
The different rate of rebleeding in these RCTs can not be
explained only by the failure in varices eradication. The
different interval between hemorrhage and beginning of
the surgical or endoscopic treatment can be an important
factor. Different treatment intervals have been shown to
affect the incidence of variceal rebleeding.' Finally it is
a common experience that early rebleeding occurs fre-
quently in Child's C patients'4 and the number of Child's
patients differed in all these RCTs.
Hypertensive or congestive gastropathy is a serious
complication due to raised portal pressure. DSRS reduces
the gastric blood flow and prevents this complication. In
the ES group two patients (one had also a variceal re-
bleeding) had five episodes ofbleeding due to gastropathy.
The evident temporal relationship between the use ofbeta-
blockers and hemorrhage control supports its therapeutic
efficacy. This concomitant therapy in the ES group was
used only after digestive hemorrhage. Patients with en-
doscopic findings of congestive gastropathy, without
hemorrhage, were not prophylactically treated with beta-
blocker agents.
The 2-year survival rate ranged from 59% to 95% in
DSRS and from 61% to 90% in the ES group (Table 3).
Why are there these great differences?
The different incidence in these studies of two prog-
nostic factors (Child's class C patients and the interval
between hemorrhage and treatment) can explain these
results.4' However a more important factor is present in
the ES group: the fate ofthe patient after variceal rebleed-
ing (Table 3). The fact that some studies'5"6 do not have
a good therapeutic option in the case of ES failure can
influence these results. The best survival rate reported in
Warren's study'4 seems to be due to the large number of
ES patients submitted to shunt surgery (10 of 36 patients)
with a low operative mortality rate (10%). This advantage
was not shown in the other studies.'5"'6 This can be ex-
plained by the fact that shunt surgery compromises liver
function, thus death due to liver failure becomes the major
cause of death instead of hemorrhage.33 In fact, in our
study, DSRS patients had significantly decreased liver
function 1 year after shunt surgery, when compared to
the preoperative values (0.54 ± 0.10 versus 0.61 ± 0.11).
The mean difference was 0.07, with a 95% confidence
interval from -0.001 to 0.141. We do not know the actual
clinical significance of this difference, even if statistically
significant. The ES patients, on the other hand, did not
show any impairment in liver function. This might be
explained by the fact that patients in the ES group with
alcoholic cirrhosis eliminated alcohol abuse, resulting in
improved liver function.
The main complication for the shunted patient was
chronic HE that little affected ES patients. In the four
RCTs the incidence ofHE was higher in the DSRS group
than in the ES group. This trend became significant in
Teres' study,'5 probably due to the modified technique
used, which did not associate portal-azygos disconnection
with splenorenal shunt. In fact the entity of collaterals
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after DSRS seems to be an important factor influencing
the incidence of HE.4245 In Rikkers"6 and Warren's'4
studies chronic HE was probably attributed to the hepatic
failure, and that was due to the fact that both Child's C
patients'4,16 and total shunts'6 were taken in consideration.
In our study,'7 the low rate of chronic HE in the DSRS
group could be due to the recruitment of patients with
good liver function and a shorter follow-up period than
in other studies. The results ofthe psychometric tests and
EEG confirmed the similar outcomes in the two groups
of patients at 1-year follow-up evaluation.
ES was more often complicated by ascites than was
DSRS. However ascites almost always responded to stan-
dard diuretic therapy. The complication rate of ES was
low. In our experience,'7 only two patients had esophageal
stenosis. This was the only complication that affected the
quality of life in the ES group. Similar rates were shown
in two RCTs'5"'6 (10%), while Warren et al.'4 had no
complications after ES.
In conclusion DSRS seems to be more effective than
ES for preventing gastroesophageal rebleeding. However
this improvement was not followed by an increase in pa-
tient survival. Indeed early survival was significantly im-
proved by ES only when shunt surgery was available for
uncontrolled bleeding.' Whether shunt rescue is an ar-
tefact of analysis or a valid phenomenon is not known.
Further investigations are necessary to confirm ifES might
be the first stage of a therapeutic regimen completed by
definitive therapy, i.e., surgery.
Which is the best treatment? In some patients the choice
is easy because it is mandatory. ES is indicated for patients
with unsuitable splenic vein or high risk of HE. DSRS is
indicated for patients with gastric variceal bleeding or re-
current hemorrhage, despite sclerotherapy. In other cases
the decision whether to shunt or to perform ES should
be made only after having carefully studied all character-
istics of every patient. To achieve good results, it is im-
portant that every time we make our decision we take
patient compliance into account. The patients should be
informed that shunt surgery is more traumatic but more
definitive for bleeding and that sclerotherapy has a min-
imal impact on hepatic functional reserve but is less ef-
fective in preventing rebleeding and demands a rigorous
follow-up.
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